Startups
OniX is actively raising funds for innovative ventures.
Interested in learning more? Contact us for details and partnership opportunities.
KTIN Therapeutics
KTIN is pioneering a novel class of therapeutics and medical food additives that restore metabolic balance and performance across species. Leveraging Dr. Karsenty’s decades of NIH-funded work on osteocalcin—a conserved bone-derived protein.​
OniX AH Biotech
OniX AH is developing PegasusX - an oral targeted drug delivery platform using HA-functionalized LNPs to deliver API directly to inflamed tissues.
KTIN: Fundraising Overview and One-Page Summary
​​​
​
​
​
- Animal Health, Food & Nutrition (Series A): $5M
- Muscle Regeneration for Human & Animal Athletes (Series A): $10M
-
Metabolic & Neurological Health in Aging (Series A): $15M
NewCo - TBN
​
NewCo is developing a MusculoPatch system to track muscle degeneration in sport injuries as well as muscle decline in aging.​​​​​​​
NewCo Fundraising overview and One-Pager Summary:
-
MusculoPatch (Pre-seed): $1M
OniX AH: Fundraising Overview and One-Page Summary
-
Animal Health (Series A): $500K – $1M
KTIN Therapeutics: Osteocalcin Analogs
KTIN Therapeutics is a Columbia University spinout developing first-in-class osteocalcin peptide analogs (OCN-PAs) to treat muscle decline (sarcopenia, cachexia, sports recovery), cognitive impairment, metabolic diseases (T2D, obesity), and rare neuromuscular disorders (like OI, SMA, LGMD). Backed by 20+ years of research from Dr. Gerard Karsenty and $10M+ in NIH funding, their platform leverages osteocalcin’s natural, multi-system benefits — enhancing muscle function, cognition, and metabolism simultaneously.
